BASF Aims for Top Spot in Omega-3 API Market with Pronova BioPharma Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 12 (Table of Contents)
Published: 10 Dec-2012
DOI: 10.3833/pdr.v2012.i12.1858 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In order to attain a leading position in the global omega-3 API market, the German chemical company BASF has made a voluntary offer to acquire Pronova BioPharma, the originator of the blockbuster omega-3 derived drug Lovaza®/Omacor® (omega-3-acid ethyl esters), for a total enterprise value of NOK4845 M (US$844 M)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS